(Q38151193)

29 August 2017

title

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer (English)

1 reference

Pierluigi Benedetti Panici

29 August 2017

1 reference

1 reference

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author

series ordinal

6

object named as

Pierluigi Benedetti Panici

1 reference

29 August 2017

Davide Caruso

4

0 references

Federica Tomao

object named as

Federica Tomao

series ordinal

1

1 reference

ORCID Public Data File 2021

Anselmo Papa

series ordinal

2

object named as

Anselmo Papa

1 reference

29 August 2017

7

Silverio Tomao

1 reference

29 August 2017

5

Federica Zoratto

1 reference

29 August 2017

Luigi Rossi

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

11 October 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

23

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

37-53

1 reference

29 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Tumor-derived microvesicles: the metastasomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Emerging role of pemetrexed in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Bevacizumab and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

The influence of microvessel density on ovarian carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

The prognostic value of endoglin (CD105) expression in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular endothelial growth factor as a target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Overview of anti-angiogenic agents in development for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Regulation of angiogenesis by hypoxia: role of the HIF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Regulatory T cells in ovarian cancer: biology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Angiogenesis in normal and neoplastic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Antiangiogenic drugs in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Natural killer lymphocytes: biology, development, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular endothelial growth factor in ovarian cyst fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Regulation of tumor angiogenesis by EZH2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

MicroRNA expression profiles in serous ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

EphA2 overexpression is associated with angiogenesis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular disrupting agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Aflibercept in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Antitumor and antivascular effects of AVE8062 in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.839657

10.1517/13543784.2013.839657

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference